Group plans $2.8B mall buy from firm with heavy Simon ownership
Carrefour SA joined a group of institutional investors to buy 127 European shopping malls in a $2.75 billion deal with Klepierre SA, which is 29-percent owned by Simon Property Group.
Carrefour SA joined a group of institutional investors to buy 127 European shopping malls in a $2.75 billion deal with Klepierre SA, which is 29-percent owned by Simon Property Group.
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
General Motors Co. named Mary Barra to succeed Dan Akerson as chief executive officer, making her the first female CEO in the global automotive industry. Former Cummins Inc. CEO and chairman Tim Solso was named GM's chairman.
Tornadoes and thunderstorms that swept across the U.S. Midwest last month will probably cost more than $1 billion in economic losses, led by damage in Illinois and Indiana, according to insurance broker Aon Plc.
Head-trauma lawsuits by ex-football players filed against the NCAA defy easy consolidation—unlike National Football League cases consolidated by federal judges and later settled for $765 million.
Edivoxetine, a derivative of Lilly's Strattera drug for attention deficit disorder, was in the final of three stages of testing usually required for marketing approval by U.S. regulators.
Novartis AG’s animal-health business is drawing interest from drugmakers including Indianapolis-based Eli Lilly and Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of the matter said.
The Indiana Pacers were the first NBA team to jump on the opportunity to sell advertising on the court. So far, just two other teams have followed suit.
Faced with smaller crowds of less confident consumers, as well as six fewer days between Thanksgiving and Christmas than last year, retailers are pouring on margin-eating discounts to grab market share.
Companies that build private toll roads are pressing states, including Indiana, to assume more financial risk of traffic not meeting expectations, a change that benefits the operators while threatening to increase taxpayer costs.
When Democrat Bill de Blasio takes office in New York City on Jan. 1, Indianapolis will become the most populous U.S. city run by a Republican mayor.
J.C. Penney, which is trying to bounce back from its worst sales year in two decades, will be replaced by Carmel-based electronic security company Allegion, which is being spun off by Irish industrial conglomerate Ingersoll-Rand Plc.
The U.S. Consumer Financial Protection Bureau is investigating at least two for-profit colleges, including ITT Educational Services Inc., over potentially abusive practices in marketing and originating student loans.
Toyota Motor Corp.’s top North American executive said the carmaker hasn’t decided to end a production deal that supplies it with 100,000 Camry sedans annually from Fuji Heavy Industries Ltd.’s U.S. Subaru plant in Lafayette.
The National Collegiate Athletic Association sued Electronic Arts Inc., saying the video-game maker hasn’t agreed to indemnify the NCAA for legal claims by college athletes and hasn’t maintained insurance to do so.
The messy rollout of the insurance exchanges has made it hard for carriers to figure out what business will be like in 2014.
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
The sheer size puts Indiana University’s Kelley School of Business in a small group of schools with such massive networks. The school has alumni in all 50 states, Washington, D.C., and 106 different countries.
Testosterone replacement drugs, a $1.6 billion market for Eli Lilly and Co. and others, boosted the odds of having a heart attack, stroke or dying by 29 percent in one of the first studies weighing the therapy's cardiovascular risks.
Indianapolis-based Eli Lilly and Co., Bayer AG and Boehringer Ingelheim GmbH are among companies that may consider an offer if the Swiss drugmaker proceeds with the animal-health sale.